SCHEMBL3584400

SCHEMBL3584400

Cc1c(C(=O)N(C)Cc2ccc3ncccc3c2)[nH]c(C(N)=O)c1S(=O)(=O)c1cc(F)cc(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 1/20 0.38
PDK1 Q15118 2/20 0.37
USP30 Q70CQ3 1/20 0.35
MAPK1 P28482 2/20 0.34
ALDH1A1 P00352 1/20 0.34
RAB9A P51151 1/20 0.34
TNF P01375 1/20 0.33
NOD2 Q9HC29 1/20 0.33
NOD1 Q9Y239 1/20 0.33
AGTR2 P50052 1/20 0.32
RECQL P46063 1/20 0.32
NPC1 O15118 1/20 0.32
DAO P14920 1/20 0.32
SCN9A Q15858 1/20 0.32
JAK1 P23458 1/20 0.32
BRD4 O60885 1/20 0.31
BRD3 Q15059 1/20 0.31
NAMPT P43490 1/20 0.31
HDAC3 O15379 1/20 0.31
TUBB4A P04350 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3590929 0.95 SPR (0.40) SPRPDK1USP30MAPK1ALDH1A1
SCHEMBL3590814 0.89 PTGDR2 (0.32) ALDH1A1
SCHEMBL3583754 0.88 SPR (0.41) SPRPDK1USP30MAPK1ALDH1A1
SCHEMBL3585616 0.86 TACR1 (0.32)
SCHEMBL3588250 0.85 ATM (0.42) ALDH1A1RAB9ABRD4BRD3
SCHEMBL3575304 0.85 KDM4E (0.32) ALDH1A1RECQLSCN9ANAMPT
SCHEMBL3590262 0.84 SPR (0.38) SPRPDK1USP30MAPK1ALDH1A1
SCHEMBL3593677 0.83 NAMPT (0.38) SPRPDK1USP30MAPK1ALDH1A1
SCHEMBL3585272 0.83 EDNRB (0.34) ALDH1A1RECQL
SCHEMBL3586923 0.81 TACR1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US claimed
EP-2076492-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2009-07-08 EP claimed
WO-2008054605-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2008-05-08 WO claimed
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS RTF1, RNGTT, POLR2E SPR 217/4885PDK1 1786/4885USP30 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.